[1] Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016, 375(7):631-643. [2] Gideon, M, Hirschfield H. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis- science direct. J Hepatol, 2017, 67(1):145-172. [3] Cheung A, Larusso N, Gores G, et al. Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis. Semin Liver Dis, 2017, 37(2):159-174. [4] 李博, 王绮夏, 马雄. 自身免疫性肝病2016年研究进展. 中华肝脏病杂志, 2017, 25(2):100-104. [5] 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015). 中华肝脏病杂志,2016, 24(1):5-13. [6] Samur S, Klebanoff M, Banken R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology, 2017, 65(3):920-928. [7] Harms M H, Lammers W J, Thorburn D, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol, 2018, 113(2):254-264. [8] 靳睿, 王晓晓, 王力华, 等. 抗线粒体抗体与原发性胆汁性胆管炎临床血清学和肝硬化指标的相关性. 中华消化杂志, 2020, 40(1):16-22. [9] Yang F, Yang Y, Wang Q, et al. The risk predictive values of UK-pbc and globe scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. Aliment Pharmacol Ther, 2017, 45(5):733-743. [10] Thakran S, Sharma P, Attia R R, et al. Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem, 2013, 288(2):807-818. [11] Elias S, Kouroumalis JH, Demetrius RE, et al. Biomarkers for primary biliary cholangitis: current perspectives. Hepat Med, 2018, 18(10):43-53. [12] Wong K A, Bahar R, Liu C H, et al. Current treatment options for primary biliary cholangitis. Clin Liver Dis, 2018, 22(3):481-500. [13] Johann O, Luzia V, Tatjana S, et al. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab, 2011, 97(2):535-542. [14] Green J R B, Snitcher E J, Mowat N A G, et al. Thyroid function and thyroid regulation in euthyroid men with chronic liver disease: evidence of multiple abnormalities. Clin Endocrinol, 2010, 7(6):453-461. [15] Ta A, Kklü S, Beyazit Y, et al. Thyroid hormone levels predict mortality in intensive care patients with cirrhosis. Am J Med Sci, 2012, 344(3):175-179. [16] Petta S, Mazzola A, Grimaudo S, et al. 919 thyroid-stimulating hormone serum level,liver thyroid-stimulating hormone-receptor,and severe fibrosis in genotype 1 chronic hepatitis c patients with normal thyroid function. J Hepatol, 2012, 56(12):S358-S358. [17] 赵家军. 甲状腺疾病与肝脏. 中华肝脏病杂志, 2014, 22(3):165-167. [18] Lleo A, Marzorati S, Anaya J M, et al. Primary biliary cholangitis: a comprehensive overview. Hepatol Int, 2017, 11(6):485-499. [19] Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol, 2018[Epub ahead of print]. [20] 郭锐, 覃进. 随机对照试验研究熊去氧胆酸治疗原发性胆汁性肝硬化患者的疗效和安全性.实用肝脏病杂志,2017, 20(1):109-110. [21] Goel A, Kim W R. Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems. Clin Liver Dis, 2018, 22(3):563-578. [22] Hu Z, Ni P, Fan X, et al. Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol, 2019,31(2):277. |